Hormonal
Inulin-propionate ester (IPE) supplementation reduces systemic proinflammatory interleukin-8 (IL-8) levels in adults with overweight and obesity, an effect not observed with inulin alone.
For those managing obesity, IPE supplementation may offer an anti-inflammatory benefit by lowering IL-8, a marker linked to insulin resistance. This effect was specific to IPE and not seen with standard inulin, suggesting the targeted delivery of propionate plays a unique role in reducing systemic inflammation.
iPe supplementation decreased proinflammatory interleukin-8 levels compared with cellulose, while inulin had no impact on the systemic inflammatory markers studied.
Why this rating
Supported by in vivo human trial data and in vitro PBMC analysis.
Source
Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial
Edward S. Chambers et al. · Gut · 2019
DOI 10.1136/gutjnl-2019-318424
More from this paper
- Supplementation with 20 g/day of inulin-propionate ester (IPE) or inulin for 42 days improves insulin sensitivity in adults with overweight and obesity compared to cellulose.Good
- Inulin supplementation promotes a bifidogenic effect (increased Bifidobacterium) and alters gut bacterial composition at the class and order levels, whereas IPE primarily affects bacterial populations at the species level.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →